Novartis AG$154.41ABBV · NYSE
The supplied consensus is Buy across 22 analysts, with a mean price target of $275. Targets cluster only insofar as the average is available; the low and high are not reported, so the width of the target range cannot be established. The record does not identify the most bullish or least bullish analyst, nor does it provide a complete set of weekly revisions. One attributable change was positive: Barclays raised its target from $275 to $300 on July 29. The substantive disagreement appears to center on whether stronger Skyrizi, Rinvoq and neuroscience growth and higher revenue guidance outweigh Apogee-related EPS dilution and increased R&D spending, although the supplied data do not quantify the target spread.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Barclays PLC | — | $300 | +22.4% | Jul 29, 2026 | Open the report this row came from |
